OncoSec Medical EBIT

OncoSec Medical (ONCS) currently reports a EBIT of $-33M as of January 2023. That compares with $-44M in the prior-year period — up 25.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore OncoSec Medical's EBIT history and peer comparisons.

OncoSec Medical's EBIT increased from $-44M to $-33M — a 25.2% year-over-year increase (period ending January 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

OncoSec Medical's EBIT of $-33M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

OncoSec Medical reported $-33M in EBIT as of January 2023. That compares with $-44M in the prior-year period — up 25.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-33M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for OncoSec Medical, and consider following ONCS for alerts when major investors trade the stock.